GoAI
Get started
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc.

GYRE

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$6.61

−$0.30 · -4.34%

Aug 24, 2:14 PM ET

GYRE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

49

Fair Value

Momentum

35

Weakening

Sentiment

42

Mixed

Risk resilience

14

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Ying Luo
Listed since
Apr 12, 2006
Employees
625

Market position

Day range

Current $6.61

52-week range

Current $6.61

Open
$6.89
Previous close
$6.91
Volume
24.05K
0.29× average
Average volume
82.18K
Average daily volume
Market cap
736.94M USD
Beta
4.82
Market reference 1
50-day average
$6.384
+3.54% above average
200-day average
$7.2006
-8.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
594.64M USD
P/E (TTM)
-33.23×
P/B (TTM)
5.1×
P/S (TTM)
6.17×
EV / EBITDA
35.07×
Earnings yield
0.80%
Free cash flow yield
-0.03%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
94.30%
Operating margin
-13.97%
Net margin
-14.52%
Return on equity
4.74%
Return on assets
3.03%
Return on invested capital
5.30%

Financial health

Debt / equity
0.03×
Current ratio
5.6×
Altman Z-score
13.39
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends226%-292%-810%-1328%Gross margin, FY2021: -4.52%Gross margin, FY2022: 95.31%Gross margin, FY2023: 95.91%Gross margin, FY2024: 96.33%Gross margin, FY2025: 95.35%Operating margin, FY2021: -1140.99%Operating margin, FY2022: 9.00%Operating margin, FY2023: -59.26%Operating margin, FY2024: 15.35%Operating margin, FY2025: 9.86%Net margin, FY2021: -1198.32%Net margin, FY2022: 2.25%Net margin, FY2023: -81.92%Net margin, FY2024: 11.43%Net margin, FY2025: 4.31%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -4.52%. Gross margin FY2022 95.31%. Gross margin FY2023 95.91%. Gross margin FY2024 96.33%. Gross margin FY2025 95.35%. Operating margin FY2021 -1140.99%. Operating margin FY2022 9.00%. Operating margin FY2023 -59.26%. Operating margin FY2024 15.35%. Operating margin FY2025 9.86%. Net margin FY2021 -1198.32%. Net margin FY2022 2.25%. Net margin FY2023 -81.92%. Net margin FY2024 11.43%. Net margin FY2025 4.31%.

Income trends

Revenue

116.59M USD+10.24%

Operating income

11.49M USD-29.19%

Net income

5.03M USD-58.40%
Income trends across reported periods137.54M USD53.73M USD−30.08M USD−113.89M USDRevenue, FY2021: 7.34M USDRevenue, FY2022: 102.29M USDRevenue, FY2023: 113.45M USDRevenue, FY2024: 105.76M USDRevenue, FY2025: 116.59M USDOperating income, FY2021: −83.73M USDOperating income, FY2022: 9.2M USDOperating income, FY2023: −67.23M USDOperating income, FY2024: 16.23M USDOperating income, FY2025: 11.49M USDNet income, FY2021: −87.93M USDNet income, FY2022: 2.3M USDNet income, FY2023: −92.93M USDNet income, FY2024: 12.09M USDNet income, FY2025: 5.03M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.34M USD. Revenue FY2022 102.29M USD. Revenue FY2023 113.45M USD. Revenue FY2024 105.76M USD. Revenue FY2025 116.59M USD. Operating income FY2021 −83.73M USD. Operating income FY2022 9.2M USD. Operating income FY2023 −67.23M USD. Operating income FY2024 16.23M USD. Operating income FY2025 11.49M USD. Net income FY2021 −87.93M USD. Net income FY2022 2.3M USD. Net income FY2023 −92.93M USD. Net income FY2024 12.09M USD. Net income FY2025 5.03M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue116.59M USD105.76M USD113.45M USD102.29M USD7.34M USD
Cost of goods sold5.42M USD3.88M USD4.64M USD4.79M USD7.67M USD
Gross profit111.17M USD101.87M USD108.81M USD97.5M USD−332K USD
Research and development13.7M USD12.02M USD13.78M USD16.69M USD64.57M USD
Selling, general, and administrative85.98M USD73.62M USD75.82M USD71.61M USD18.82M USD
Operating expenses99.68M USD85.71M USD176.04M USD88.29M USD83.39M USD
Interest income1.75M USD1.55M USD1.04M USD726K USD39K USD
Depreciation and amortization2.52M USD1.59M USD1.11M USD1.13M USD290K USD
Operating income11.49M USD16.23M USD−67.23M USD9.2M USD−83.73M USD
Net income5.03M USD12.09M USD−92.93M USD2.3M USD−87.93M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
25%
2 beats, 5 misses, 1 met estimate
Average EPS surprise
-56.05%
8 comparable reports
Latest EPS result
-0.12
Estimate -0.06 · Miss by 111.75%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.10-0.09-0.19Q1 '25MissQ2 '25MetQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual 0.01, estimate 0.04, surprise -75.00%, Miss. Q2 2025, reported May 9, 2025: actual 0.03, estimate 0.03, surprise 0.00%, Met estimate. Q3 2025, reported Aug 11, 2025: actual 0.02, estimate 0.03, surprise -33.33%, Miss. Q4 2025, reported Nov 7, 2025: actual 0.06, estimate 0.05, surprise +20.00%, Beat. Q1 2026, reported Mar 12, 2026: actual -0.019, estimate 0.057, surprise -133.35%, Miss. Q2 2026, reported May 7, 2026: actual -0.05, estimate -0.06, surprise +16.67%, Beat. Q3 2026, reported Aug 7, 2026: actual -0.12, estimate -0.057, surprise -111.75%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate -0.15, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates38.68M32.65M26.61M20.57MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual 27.87M USD, estimate 23.5M USD, surprise +18.60%, Beat. Q2 2025, reported May 9, 2025: actual 22.06M USD, estimate 28.4M USD, surprise -22.33%, Miss. Q3 2025, reported Aug 11, 2025: actual 26.77M USD, estimate 30.8M USD, surprise -13.08%, Miss. Q4 2025, reported Nov 7, 2025: actual 30.56M USD, estimate 32.93M USD, surprise -7.18%, Miss. Q1 2026, reported Mar 12, 2026: actual 37.2M USD, estimate 35.43M USD, surprise +4.97%, Beat. Q2 2026, reported May 7, 2026: actual 22.52M USD, estimate 31.61M USD, surprise -28.75%, Miss. Q3 2026, reported Aug 7, 2026: actual 29.11M USD, estimate 26.49M USD, surprise +9.87%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate 28.4M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$17.00

157.19% upside
Past 12 months12-month forecastHigh $18.00Average $17.00Low $16.00

GYRE news

zacks.com

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.

Read source
globenewswire.com

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China's CDE in May 2026…

Read source
globenewswire.com

Gyre Therapeutics Appoints Three New Members to its Board of Directors

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United…

Read source
newsfilecorp.com

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) ("Gyre") on behalf of the company's long-term shareholders. The investigation seeks…

Read source
zacks.com

New Strong Sell Stocks for May 27th

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend Jan 13, 2023

$0.24

Quarterly

Record Jan 5, 2023

Dividend

Ex-dividend Sep 21, 2022

$1.43

Quarterly

Record Sep 6, 2022

Dividend

Ex-dividend Aug 20, 2015

$0.569

Quarterly

GYRE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.91

+0.36%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.41

+0.20%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$549.02

+0.18%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.28

-0.67%

Sanofi logo

SNY

Sanofi

$45.63

-0.48%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$826.32

-0.93%

ETFs holding GYRE

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.53M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.86—
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
2.67M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$297.45—
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.37M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.03—
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
833.17K
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$382.46—
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
684.72K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.3821—
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
596.38K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.26—
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
285.83K
Weight
0.00%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$223.76—
WisdomTree U.S. SmallCap Fund logoWisdomTree U.S. SmallCap FundEES
Market value
139.98K
Weight
0.02%
AUM
739.61M USD
Expense ratio
0.38%
Price / 1D
$68.185—

Continue in GoAI

Research GYRE

research.disclaimer